|
|
144 - 4th Ave. Southwest Suite 1010
Calgary, Alberta T2P 3N4 Canada
phone:
(403) 237-7272
fax:
(403) 237-6565 |
| Symbol |
WED |
| Exchange |
TSX |
| Founded |
0 |
| Employees |
240 |
|
|
www.westaim.com |
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Wound care and pharmaceutical products based on nanotechnology. |
 |
| Management |
| Barry M. Heck, President and Chief Executive Officer; G.A. (Drew) Fitch, Senior Vice President and Chief Financial Officer; Anthony B. Johnston, Senior Vice President; Brian D. Heck, Vice President, General Counsel and Corporate Secretary; Nicolas W. Khoury, President; NUCRYST Pharmaceuticals Corp.; Scott H. Gillis, President and Chief Executive Officer |
|
|
|
|
| Keywords |
| woundwound, woundcare |
|
|
|
|
Description |
| Westaim invests in high-potential businesses targeting large commercial markets. Its currently owns two technology businesses, iFire Technology and NUCRYST Pharmaceuticals.
NUCRYST Pharmaceuticals researches, develops and commercializes wound care and pharmaceutical products based on its noble metal nanotechnology. |
 |
| Products / Services |
NUCRYST's wound care products, Acticoat dressings with SILCRYST Nanocrystals, are designed for serious wounds, including burns and chronic wounds.
|
 |
| Market / Customers |
NUCRYST's SILCRYST nanocrystals are marketed, sold and distributed globally by Smith & Nephew. Acticoat dressings are sold in 30 countries.
|
 |
| Status |
| NUCRYST's first dermatology drug, NPI 32101, is based on its platform nanocrystalline silver technology. |
 |
|
|
|
|